الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 108 |  |  |
| | | from | 108 | | |
Abstract
OSA is characterized by repetitive episodes of disrupted breathing during sleep and recurrent decreases in blood oxygen saturation. It is exceedingly common in the pediatric population. The most common cause of severe pediatrictender or enlarged (>2 cm) lymph nodes), tonsillar or pharyngeal exudate, positive culture for group A β-hemolytic streptococcus), children with history of cardiorespiratory, neurologic, allergic, craniofacial, immunodeficiency, or genetic disorders, children suffering from diseases affect IL-8 level as: acute pyelonephritis, nosocomial bacterial infections, vesicoureteral reflux, rheumatoid arthritis, cancer, obesity, otitis media, COVID-19 patients with severe diseases and Hepatitis C, children prescribed on drugs affect IL-8 level as: OSA is adenotonsillar hypertrophy and T&A remains the recommended first line treatment.
It was founded that in young children with sleep-related chronic intermittent hypoxia, an enhanced production capacity of IL-8 precedes the development of systemic inflammatory markers.
A randomized single arm pre-post prospective study was carried out to evaluate serum IL-8 level after adenotonsillectmy in children with obstructive sleep apnea.
Our study was carried out on 30 children with OSA attending ENT department of Suez Canal University Hospital. Including, children with symptoms of OSA and sleep-related CIH, and children will undergo an elective T&A.
Excluding, children with acute tonsillitis (fever > 38.3°C, cervical lymphadenopathy (